- /
- Supported exchanges
- / US
- / ARCT.NASDAQ
Arcturus Therapeutics Holdings Inc (ARCT NASDAQ) stock market data APIs
Arcturus Therapeutics Holdings Inc Financial Data Overview
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arcturus Therapeutics Holdings Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Arcturus Therapeutics Holdings Inc data using free add-ons & libraries
Get Arcturus Therapeutics Holdings Inc Fundamental Data
Arcturus Therapeutics Holdings Inc Fundamental data includes:
- Net Revenue: 82 031 K
- EBITDA: -73 235 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: 4.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcturus Therapeutics Holdings Inc News
New
Cathie Wood's ARK boosts Palantir, Tesla, Roninhood bets; cuts semiconductor exposure
Joe Raedle Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitica...
Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play
Cathie Wood’s ARK Invest has been steadily dialing down its exposure to mega-cap tech, trimming names like Nvidia (NVDA), Meta (META), AMD (AMD), and Tesla (TSLA) amid valuation and regulatory conce...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
It seems as if Cathie Wood can't have nice things. The founder and CEO of the Ark Invest family of aggressive-growth exchange-traded funds (ETFs) had a market-thumping performance in 2020, only to fal...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
These are challenging times for Cathie Wood's style of investing. The co-founder, CEO, and investor at Ark Invest finds her family of aggressive growth exchange-traded funds losing to the market for t...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.